Overview

Clinical Study of DA-001 as a Treatment for Telogen Effluvium

Status:
NOT_YET_RECRUITING
Trial end date:
2026-04-17
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for telogen effluvium
Phase:
PHASE3
Details
Lead Sponsor:
Applied Biology, Inc.
Collaborators:
Daniel Alain, Inc.
Follea International Limited
Treatments:
Phenylephrine